emerge.png
Emergent BioSolutions Reports Financial Results For First Quarter 2023
May 09, 2023 16:05 ET | Emergent BioSolutions
Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101MUpdates FY 2023 guidance and provides initial Q2 2023 guidance ...
emerge.png
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
February 27, 2023 16:42 ET | Emergent BioSolutions
Reports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M, in line with prior guidanceReports Q4 2022 net loss of $88M and FY 2022 net loss of $224MReports Q4 2022...
emerge.png
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
August 01, 2022 16:05 ET | Emergent BioSolutions
Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segmentResumes financial guidance; provides update to full year...
emerge.png
Emergent BioSolutions Reports Financial Results For First Quarter 2022
April 28, 2022 16:05 ET | Emergent BioSolutions
Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36MTemporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG,...
emerge.png
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
April 08, 2022 06:30 ET | Emergent BioSolutions
GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial...
emerge.png
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
February 24, 2022 16:05 ET | Emergent BioSolutions
Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidanceUpdates full year 2022...
emergent logo.jpg
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
July 29, 2021 16:05 ET | Emergent BioSolutions
Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second...
emergent logo.jpg
Emergent BioSolutions Reports Financial Results for First Quarter 2021
April 29, 2021 16:05 ET | Emergent BioSolutions
Revises 2021 Financial Forecast GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter ended March 31, 2021. ...
emergent logo.jpg
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
February 18, 2021 16:05 ET | Emergent BioSolutions
Reports record fourth quarter and year to date 2020 performance, in line with prior guidanceReaffirms full year 2021 forecast GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) --...
emergent logo.jpg
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
November 05, 2020 16:05 ET | Emergent BioSolutions
Reports strong third quarter and record year to date performanceUpdates full year guidance — refines revenue ranges and raises profitability ranges GAITHERSBURG, Md., Nov. 05, 2020 (GLOBE NEWSWIRE)...